Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Wainberg, Zev A.; Enzinger, Peter C.; Kang, Yoon-Koo; Yamaguchi, Kensei; Qin Shukui, Qin Shukui; Lee, Keun-Wook; Oh, Sang Cheul; Li Jin, Li Jin; TÜRK, HACI MEHMET; Teixeira, Alexandra Carolina; Cardellino, Giovanni Gerardo; Guardeno, Raquel; Mitra, Siddhartha; Yang Yingsi, Yang Yingsi; Collins, Helen; Catenacci, Daniel V. T.

Publication:
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

dc.contributor.author	Wainberg, Zev A.
dc.contributor.author	Enzinger, Peter C.
dc.contributor.author	Kang, Yoon-Koo
dc.contributor.author	Yamaguchi, Kensei
dc.contributor.author	Qin Shukui, Qin Shukui
dc.contributor.author	Lee, Keun-Wook
dc.contributor.author	Oh, Sang Cheul
dc.contributor.author	Li Jin, Li Jin
dc.contributor.author	TÜRK, HACI MEHMET
dc.contributor.author	Teixeira, Alexandra Carolina
dc.contributor.author	Cardellino, Giovanni Gerardo
dc.contributor.author	Guardeno, Raquel
dc.contributor.author	Mitra, Siddhartha
dc.contributor.author	Yang Yingsi, Yang Yingsi
dc.contributor.author	Collins, Helen
dc.contributor.author	Catenacci, Daniel V. T.
dc.contributor.institutionauthor	TÜRK, HACI MEHMET
dc.date.accessioned	2021-04-20T20:59:07Z
dc.date.available	2021-04-20T20:59:07Z
dc.date.issued	2021-01-01T00:00:00Z
dc.identifier.citation	Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021
dc.identifier.doi	10.1200/jco.2021.39.3_suppl.160
dc.identifier.uri	http://hdl.handle.net/20.500.12645/28794
dc.identifier.wos	WOS:000636712800195
dc.title	Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
dc.type	Article
dspace.entity.type	Publication
local.avesis.id	ed5fe60a-be3f-4315-b2ec-1cc4bc75ff87
local.indexed.at	WOS
local.publication.isinternational	1
relation.isAuthorOfPublication	1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery	1b3a1540-7e57-405d-8a9d-f926d17dcc29

Collections

Yayınlar - Eserler

Publication: Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Files

Collections

Publication:
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).